Valproic Acid Inhibits the Release of Soluble CD40L Induced by Non-Nucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus Infected Individuals

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Davidson, Donna C ^a   Schifitto, Giovanni ^a   Maggirwar, Sanjay B ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; CD40 LIGAND; EFAVIRENZ; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVATION; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; PROTEIN PHOSPHORYLATION; SIDE EFFECT; THROMBOCYTE;

BENZOXAZINES; BLOOD PLATELETS; BLOOD-BRAIN BARRIER; CD40 LIGAND; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HIV INFECTIONS; HUMANS; MALE; MAP KINASE KINASE 4; PERMEABILITY; PHOSPHORYLATION; REVERSE TRANSCRIPTASE INHIBITORS; VALPROIC ACID;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875486997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059950     Document Type: Article

References (47)

1. McArthur JC, Steiner J, Sacktor N, Nath A, (2010) Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol 67: 699-714.
2. Minagar A, Commins D, Alexander JS, Hoque R, Chiappelli F, et al. (2008) NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS. Mol Diagn Ther 12: 25-43.
3. Boisse L, Gill MJ, Power C (2008) HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 26: 799-819, x.
4. Hult B, Chana G, Masliah E, Everall I, (2008) Neurobiology of HIV. Int Rev Psychiatry 20: 3-13.
5. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, et al. (2008) Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 20: 25-31.
6. Kaul M, Garden GA, Lipton SA, (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988-994.
7. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, et al. (2007) Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol 178: 3226-3236.
8. Davidson DC, Hirschman MP, Sun A, Singh MV, Kasischke K, et al. (2012) Excess Soluble CD40L Contributes to Blood Brain Barrier Permeability In Vivo: Implications for HIV-Associated Neurocognitive Disorders. PLoS One 7: e51793.
9. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR, (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106: 896-899.
10. Wachtman LM, Skolasky RL, Tarwater PM, Esposito D, Schifitto G, et al. (2007) Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus-associated dementia. Arch Neurol 64: 1264-1272.
11. Ragin AB, D'Souza G, Reynolds S, Miller E, Sacktor N, et al. (2011) Platelet decline as a predictor of brain injury in HIV infection. J Neurovirol 17: 487-495.
12. D'Aversa TG, Weidenheim KM, Berman JW, (2002) CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis. Am J Pathol 160: 559-567.
13. Ramirez SH, Fan S, Dykstra H, Reichenbach N, Del Valle L, et al. (2010) Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis. J Neurosci 30: 9454-9464.
14. Sipsas NV, Sfikakis PP, Kontos A, Kordossis T, (2002) Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts. Clin Diagn Lab Immunol 9: 558-561.
15. Romano MF, Buffolano W, Bisogni R, Russo R, Liuzzi R, et al. (2006) Increased CD154 expression in uninfected infants born to HIV-positive mothers exposed to antiretroviral prophylaxis. Viral Immunol 19: 363-372.
16. Corrales-Medina VF, Simkins J, Chirinos JA, Serpa JA, Horstman LL, et al. (2010) Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54: 217-218.
17. Chini M, Tsoupras AB, Mangafas N, Tsogas N, Papakonstantinou VD, et al. (2012) Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen. Int J Immunopathol Pharmacol 25: 247-258.
18. Baum PD, Sullam PM, Stoddart CA, McCune JM, (2011) Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 25: 2243-2248.
19. Satchell CS, O'Halloran JA, Cotter AG, Peace AJ, O'Connor EF, et al. (2011) Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis 204: 1202-1210.
20. Davidson DC, Hirschman MP, Spinelli SL, Morrell CN, Schifitto G, et al. (2011) Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals. J Immunol 186: 584-591.
21. Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, et al. (2003) Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 23: 9162-9170.
22. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, et al. (2006) Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66: 919-921.
23. Dash PK, Orsi SA, Zhang M, Grill RJ, Pati S, et al. (2010) Valproate administered after traumatic brain injury provides neuroprotection and improves cognitive function in rats. PLoS One 5: e11383.
24. DiCenzo R, Peterson D, Cruttenden K, Morse G, Riggs G, et al. (2004) Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 48: 4328-4331.
25. O'Brien JJ, Spinelli SL, Tober J, Blumberg N, Francis CW, et al. (2008) 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes. Blood 112: 4051-4060.
26. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, et al. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15: 71-75.
27. Adam F, Kauskot A, Nurden P, Sulpice E, Hoylaerts MF, et al. (2010) Platelet JNK1 is involved in secretion and thrombus formation. Blood 115: 4083-4092.
28. Yacoub D, Hachem A, Theoret JF, Gillis MA, Mourad W, et al. (2010) Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol 30: 2424-2433.
29. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
30. Adle-Biassette H, Chretien F, Wingertsmann L, Hery C, Ereau T, et al. (1999) Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol Appl Neurobiol 25: 123-133.
31. Kaul M, (2009) HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol 22: 315-320.
32. Bossi P, Dupin N, Coutellier A, Bricaire F, Lubetzki C, et al. (1998) The level of human immunodeficiency virus (HIV) type 1 RNA in cerebrospinal fluid as a marker of HIV encephalitis. Clin Infect Dis 26: 1072-1073.
33. Glass JD, Fedor H, Wesselingh SL, McArthur JC, (1995) Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 38: 755-762.
34. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M, (2002) Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 185: 456-462.
35. Hermann A, Rauch BH, Braun M, Schror K, Weber AA, (2001) Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12: 74-82.
36. Ridker PM, Buring JE, Rifai N, (2001) Soluble P-selectin and the risk of future cardiovascular events. Circulation 103: 491-495.
37. Burger PC, Wagner DD, (2003) Platelet P-selectin facilitates atherosclerotic lesion development. Blood 101: 2661-2666.
38. Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M, (1999) Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood 94: 3800-3805.
39. Adam F, Kauskot A, Rosa JP, Bryckaert M, (2008) Mitogen-activated protein kinases in hemostasis and thrombosis. J Thromb Haemost 6: 2007-2016.
40. Li D, August S, Woulfe DS, (2008) GSK3beta is a negative regulator of platelet function and thrombosis. Blood 111: 3522-3530.
41. Barry FA, Graham GJ, Fry MJ, Gibbins JM, (2003) Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett 553: 173-178.
42. Kim S, Jin J, Kunapuli SP, (2006) Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. Blood 107: 947-954.
43. Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, et al. (2001) Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 13: 1913-1922.
44. Ances BM, Letendre S, Buzzell M, Marquie-Beck J, Lazaretto D, et al. (2006) Valproic acid does not affect markers of human immunodeficiency virus disease progression. J Neurovirol 12: 403-406.
45. Archin NM, Cheema M, Parker D, Wiegand A, Bosch RJ, et al. (2010) Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 5: e9390.
46. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, et al. (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366: 549-555.
47. Rom S, Fan S, Reichenbach N, Dykstra H, Ramirez SH, et al. (2012) Glycogen synthase kinase 3beta inhibition prevents monocyte migration across brain endothelial cells via Rac1-GTPase suppression and down-regulation of active integrin conformation. Am J Pathol 181: 1414-1425.